3-氟-5-(1-甲基吡咯烷-2-基)吡啶 | 35286-36-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氟-5-(1-甲基吡咯烷-2-基)吡啶
• 英文名称: DL-5-Fluornicotin
• 英文别名: 3-Fluoro-5-(1-methylpyrrolidin-2-yl)pyridine
• CAS: 35286-36-3
• 化学式: C₁₀H₁₃FN₂
• 分子量: 180.225
• InChiKey: WEACEDDYURLEPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

文献信息

• BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
  申请人：Genfleet Therapeutics (Shanghai) Inc.

  公开号：EP3967682A1

  公开（公告）日：2022-03-16

  Provided are a substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition, also disclosed are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.

  提供的是如公式I所示的一种替代二氢吡唑酮化合物，该化合物对RIPK1具有选择性抑制作用，以及其药用盐、立体异构体、溶剂合物或前药，其中公式中每个基团的定义在描述中有详细说明。此外，还披露了含有该化合物的药物组合物，以及在制备治疗RIPK1相关疾病或症状的药物中的使用。
• Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
  申请人：——

  公开号：US20040092508A1

  公开（公告）日：2004-05-13

  This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.

  本发明涉及使用尼古丁型乙酰胆碱受体激动剂和单胺类物质的联合作用治疗情感障碍，以及包含这些物质的制药组合物和用于本发明的化学物质。
• TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE
  申请人：Olsen M. Gunnar

  公开号：US20070265241A1

  公开（公告）日：2007-11-15

  This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substances and chemical substances for use according to the invention.

  本发明涉及使用尼古丁型乙酰胆碱受体激动剂和单胺类物质的联合作用治疗情感障碍，以及包含这些物质的药物组合物和用于本发明的化学物质。
• COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES
  申请人：Yang Jerry

  公开号：US20100260671A1

  公开（公告）日：2010-10-14

  The invention is in general directed to compounds, such as tannic acid, nicotine, nicotine derivatives and pyrrolid derivatives of nicotine, and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, compounds and methods for inhibiting ion channel activity of beta amyloid, and methods of diagnostic imaging of A/3 fibrils.

  本发明通常涉及化合物，例如单宁酸、尼古丁、尼古丁衍生物和吡咯烷基衍生物，以及用于诊断、预防或缓解淀粉样相关疾病的症状的方法，例如神经元疾病，例如阿尔茨海默病，用于抑制β淀粉样物离子通道活性的化合物和方法，以及A/3纤维的诊断成像方法。
• METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS
  申请人：Array BioPharma Inc.

  公开号：US20150005499A1

  公开（公告）日：2015-01-01

  Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.

  在哺乳动物中，用于合成用于治疗疼痛、癌症、炎症、神经退行性疾病或克鲁茨氏锥虫感染的化合物。